What are the differences between lenvatinib/lenvatinib imported drugs and domestic drugs?

Lenvatinib is a multi-target tyrosine kinase inhibitor used to treat multiple types of advanced solid tumors, including differentiated thyroid cancer, renal cell carcinoma, hepatocellular carcinoma and endometrial cancer. With its widespread promotion in clinical applications, more and more patients are beginning to pay attention to the differences between imported original drugs and domestic generic drugs. The original drug of lenvatinib was developed by Eisai of Japan and has been approved for marketing in the United States, the European Union, Japan and other regions. The version introduced in China is also the company’s original preparation and is sold domestically under the trade name “Lenvatinib”.

Domestic generic drugs are usually developed by domestic pharmaceutical companies when patents expire or policies permit. Although generic drugs must be compared with the original drugs in terms of equivalence and bioavailability before they can be marketed, in actual clinical use, some patients will still perceive subtle differences in the duration of drug efficacy, frequency of side effects, or individual tolerance. Imported original drugs have long-term international clinical use experience and mature quality control systems, and may be more trusted by medical staff in terms of stability and consistency. The domestic version has more advantages in terms of price, especially after the national medical insurance negotiations, which greatly reduces the financial burden on patients.

In addition, patients should pay attention to monitoring drug reactions when changing lenvatinib preparations and maintain close communication with their attending doctors to promptly identify whether there are fluctuations in drug efficacy or changes in adverse reactions. Generally speaking, as long as generic drugs are approved by the national drug regulatory department, they should achieve basically the same therapeutic effect as the original drugs. However, in actual selection, scientific decisions still need to be made based on the patient's condition, tolerance, economic conditions, and doctor's advice.

Reference materials:https://www.lenvima.com/